ArticleMetabolites2026
Ligustrazine Combined with Sinomenine Alleviates Central Sensitization in CCI-Induced Neuropathic Pain in Rats by Restoring Metabolic Homeostasis in the Spinal Dorsal Horn.
Article in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNeuropathic pain (NP) is a chronic pain condition caused by a lesion or disease of the somatosensory nervous system. Its development and persistence are closely associated with peripheral nociceptive input, central sensitization, neuroimmune dysregulation, and remodeling of the local metabolic microenvironment. Our previous studies demonstrated that combined treatment with ligustrazine and sinomenine ameliorates early sciatic nerve pathological damage and systemic metabolic disturbances in rats with chronic constriction injury (CCI). However, whether this combination modulates central sensitization in NP remains unclear.
objectiveThis study aimed to evaluate the effects of combined ligustrazine and sinomenine treatment on pain-related behaviors and motor function during the maintenance phase of CCI-induced neuropathic pain and to investigate the potential mechanisms underlying its attenuation of central sensitization, with particular emphasis on metabolic remodeling, neurotransmitter homeostasis, and associated regulatory molecules in the spinal dorsal horn.
methodsA rat model of CCI was established, and animals were treated with ligustrazine combined with sinomenine (12.5 + 12.5, 25 + 25, or 50 + 50 mg/kg) for 7 consecutive days. Mechanical withdrawal threshold, cold hypersensitivity, and gait behavior were assessed. A multiplex assay was used to profile 12 plasma inflammatory cytokines and pain-related mediators. Integrated transcriptomic and metabolomic analyses of the spinal dorsal horn were subsequently performed to identify key altered pathways. Oxylipin profiling, targeted neurotransmitter analysis, and quantification of metabolites associated with the arginine-polyamine pathway were further conducted to characterize alterations in the local metabolic microenvironment associated with central sensitization. Finally, quantitative real-time PCR (qRT-PCR) and Western blotting were used to evaluate molecules related to polyamine metabolism, redox homeostasis, and central sensitization.
resultsCombined ligustrazine and sinomenine treatment improved pain-related behaviors and gait dysfunction in CCI rats and partially normalized systemic inflammatory dysregulation. The ipsilateral-to-contralateral maximum contact-area ratio decreased from 102.8 ± 9.0% in the Sham group to 53.1 ± 9.7% in the Model group and recovered to 85.5 ± 4.4% in the high-dose group. Metabolomic and transcriptomic analyses identified 54 differential metabolites and 130 differentially expressed genes, respectively, following treatment. Integrated multi-omics analysis highlighted arginine-related metabolic pathways, together with alterations in neurotransmitter, polyamine, oxylipin, and redox homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.